Overview

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gilead Sciences
Immunomedics, Inc.
Treatments:
Veltuzumab